Advice
in the absence of a submission from the holder of the marketing authorisation:
bezlotoxumab (Zinplava®) is not recommended for use within NHS Scotland.
Indication under review: Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice135KB (PDF)
Medicine details
- Medicine name:
- bezlotoxumab (Zinplava)
- SMC ID:
- 1293/17
- Indication:
- Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.
- Pharmaceutical company
- MSD
- BNF chapter
- Gastro-intestinal system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 December 2017